Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,437,518
  • Shares Outstanding, K 218,996
  • Annual Sales, $ 2,159 M
  • Annual Income, $ 446,910 K
  • 60-Month Beta 0.96
  • Price/Sales 8.68
  • Price/Cash Flow 37.53
  • Price/Book 8.83
Trade INCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.63
  • Number of Estimates 2
  • High Estimate 0.83
  • Low Estimate 0.42
  • Prior Year 0.50
  • Growth Rate Est. (year over year) +26.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.12 +17.77%
on 01/06/21
98.44 -0.56%
on 01/22/21
+9.90 (+11.25%)
since 12/22/20
3-Month
80.01 +22.35%
on 11/20/20
98.44 -0.56%
on 01/22/21
+7.40 (+8.18%)
since 10/22/20
52-Week
62.48 +56.67%
on 03/23/20
110.36 -11.30%
on 07/07/20
+19.41 (+24.73%)
since 01/22/20

Most Recent Stories

More News
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

INCY : 97.89 (+4.25%)
NVS : 96.90 (+0.02%)
MGNX : 22.55 (+0.99%)
MOR : 29.39 (-1.57%)
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes

Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.

REGN : 537.78 (+0.43%)
GILD : 66.94 (-0.06%)
INCY : 97.89 (+4.25%)
LLY : 206.14 (+1.87%)
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor,...

INCY : 97.89 (+4.25%)
Incyte to Report Fourth Quarter and Year-End 2020 Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021.

INCY : 97.89 (+4.25%)
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris

Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.

ALXN : 159.73 (+1.18%)
AZN : 53.25 (+1.33%)
INCY : 97.89 (+4.25%)
NVS : 96.90 (+0.02%)
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19...

XNCR : 48.50 (+0.81%)
MOR : 29.39 (-1.57%)
INCY : 97.89 (+4.25%)
Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MOR : 29.39 (-1.57%)
XNCR : 48.50 (+0.81%)
INCY : 97.89 (+4.25%)
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening...

INCY : 97.89 (+4.25%)
CALA : 3.10 (+5.80%)
Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

ALKS : 22.19 (+3.35%)
INCY : 97.89 (+4.25%)
HALO : 49.50 (+4.21%)
MRUS : 27.20 (-0.07%)
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer

Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.

JNJ : 163.55 (+1.13%)
INCY : 97.89 (+4.25%)
BMY : 64.56 (+0.59%)
XNCR : 48.50 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

3rd Resistance Point 103.94
2nd Resistance Point 101.19
1st Resistance Point 99.54
Last Price 97.89
1st Support Level 95.14
2nd Support Level 92.39
3rd Support Level 90.74

See More

52-Week High 110.36
Last Price 97.89
Fibonacci 61.8% 92.07
Fibonacci 50% 86.42
Fibonacci 38.2% 80.77
52-Week Low 62.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar